drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese
and 30 Caucasians. J Pharmacol Exp Ther 1994;270:414–423.
Slatter JG, Su P, Sams JP, Schaaf LJ, Wienkers LC. Bioactivation of the anticancer agent
CPT-11 to SN-38 by human hepatic microsomal carboxylesterases and thein vitro
assessment of potential drug interactions. Drug Metab Dispos 1997;25:1157–1164.
Smith DA, Abel SM, Hyland R, Jones BC. Human cytochrome P450s: selectivity and
measurementin vivo. Xenobiotica 1998;28:1095–1128.
Sorich MJ, Smith PA, McKinnon RA, Miners JO. Pharmacophore and quantitative
structure activity relationship modelling of UDP-glucuronosyltransferase 1A1
(UGT1A1) substrates. Pharmacogenetics 2002;12:635–645.
Stormer E, von Moltke LL, Greenblatt DJ. Scaling drug biotransformation data from
cDNA-expressed cytochrome P-450 to human liver: a comparison of relative activity
factors and human liver abundance in studies of mirtazapine metabolism. J
Pharmacol Exp Ther 2000a;295:793–801.
Stormer E, von Moltke LL, Shader RI, Greenblatt DJ. Metabolism of the
antidepressant mirtazapinein vitro: contribution of cytochromes P-450 1A2, 2D6,
and 3A4. Drug Metab Dispos 2000b;28:1168–1175.
Tabata T, Katoh M, Tokudome S, Nakajima M, Yokoi T. Identification of the
cytosolic carboxylesterase catalyzing the 5^0 -deoxy-5-fluorocytidine formation from
capecitabine in human liver. Drug Metab Dispos 2004;32:1103–1110.
Tucker GT, Houston JB, Huang SM. Optimizing drug development: strategies to assess
drug metabolism/transporter interaction potential–towards a consensus. British J
Clin Pharmacol 2001;52:107–117.
Tugnait M, Hawes EM, McKay G, Rettie AE, Haining RL, Midha KK. N-oxygenation
of clozapine by flavin-containing monooxygenase. Drug Metab Dispos 1997;25:
524–527.
Tuvesson H, Hallin I, Persson R, Sparre B, Gunnarsson PO, Seidegard J. Cytochrome ̊
P450 3A4 is the major enzyme responsible for the metabolism of laquinimod, a novel
immunomodulator. Drug metab dispos: the biological fate of chemicals 2005;33:
866–872.
U.S. Department of Health and Human Services,U.S. Food and Drug Administration,
Center for Drug Evaluation and Research and Research (CDER).1997. Guidance for
industry - drug metabolism/drug interaction studies in the drug development process:
studiesin vitro. Available at http://www.fda.gov/cder/guidance/clin3.pdf.
U.S. Department of Health and Human Services,U.S. Food and Drug Administration,
Center for Drug Evaluation and Research (CDER),Center for Biologics Evaluation
and Research (CBER). 2001. Guidance for industry:in vivodrug metabolism/drug
interaction studies - study design, data analysis, and recommendations for dosing
and labeling. Available at http://www.fda.gov/cder/guidance/2635fnl.htm.
US Department of Health and Human Services,Food and Drug Administration, Center
for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and
Research (CBER). 2006. Draft guidance for industry: drug interaction studies - study
design, data analysis, and implications for dosing and labeling. Available at http://
http://www.fda.gov/cder/guidance/6695dft.pdf.
Uchaipichat V, Winner LK, Mackenzie PI, Elliot DJ, Williams JA, Miners JO.
Quantitative prediction ofin vivoinhibitory interactions involving glucuronidated
REFERENCES 509